Discovery and Evaluation of BMS-986260, a Potent, Selective and Orally Bioavailable TGFbetaR1 Inhibitor as an Immuno-Oncology Agent
2020
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI